Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Treace Medical Concepts ( (TMCI) ) has provided an update.
Treace Medical Concepts said Chief Commercial Officer Gaetano M. Guglielmino would depart at the close of business on April 8, 2026, with his duties redistributed among existing staff and the senior vice president of sales now reporting directly to CEO John T. Treace. To support the transition, Guglielmino entered a consulting agreement effective April 9, 2026, running through January 31, 2027, under which he will receive monthly fees, benefits and continued equity vesting.
For the quarter ended March 31, 2026, Treace reported preliminary unaudited revenue of $47.0 million to $47.2 million and anticipated cash, cash equivalents and marketable securities of about $51.9 million, up roughly $3.5 million from year-end 2025. The company also nudged its 2026 revenue outlook to a range of $202 million to $212 million, citing ongoing case volume growth tempered by demand-driven product and price mix shifts in its bunion portfolio.
The most recent analyst rating on (TMCI) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Treace Medical Concepts stock, see the TMCI Stock Forecast page.
Spark’s Take on TMCI Stock
According to Spark, TipRanks’ AI Analyst, TMCI is a Neutral.
The score is held down primarily by persistent losses and negative free cash flow alongside a clear bearish technical trend (price below all key moving averages with negative MACD). Valuation remains difficult due to negative earnings and no dividend, while the earnings call provides only partial offset via improved cash-burn trajectory and strong liquidity but with guidance implying flat-to-declining revenue and continued EBITDA losses.
To see Spark’s full report on TMCI stock, click here.
More about Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical device company focused on foot and ankle surgical solutions, including an expanded bunion correction portfolio. The company targets orthopedic and podiatric surgeons, aiming to drive case volume growth in a competitive elective surgery market that is sensitive to product mix and pricing dynamics.
Average Trading Volume: 704,737
Technical Sentiment Signal: Sell
Current Market Cap: $90.43M
Learn more about TMCI stock on TipRanks’ Stock Analysis page.